- Home
- HUYA vs GERN Comparison
HUYA vs GERN Comparison
Compare HUYA & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUYA | GERN |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.8M | 753.3M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HUYA | GERN |
|---|---|---|
| Price | $2.95 | $1.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $3.50 | $3.00 |
| AVG Volume (30 Days) | 977.5K | ★ 6.9M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | ★ 83.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $879,277,448.00 | $183,403,000.00 |
| Revenue This Year | $9.05 | $147.42 |
| Revenue Next Year | $11.33 | $39.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.40 | ★ 522.13 |
| 52 Week Low | $2.21 | $1.04 |
| 52 Week High | $4.59 | $3.68 |
Technical Indicators
Market Signals| Indicator | HUYA | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 61.37 |
| Support Level | $2.93 | $1.30 |
| Resistance Level | $3.08 | $1.37 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 23.21 | 79.17 |
Price Performance
Historical ComparisonAbout HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.